Notes From Underground: Miners Face Increased Risk of Rheumatoid Arthritis
(MedPage Today) -- Add "hard rock" mining to the list of occupations associated with high rates of rheumatoid arthritis (RA), a new study indicated, with silica exposure the presumed malefactor.
Based on survey data from men ages 50 and older... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 17, 2022 Category: American Health Source Type: news
Study: Patient Reports Can Substitute for Objective Measures in RA Evaluation
(MedPage Today) -- A model incorporating rheumatoid arthritis (RA) patients' self-reports matched conventional physician-led evaluations of disease activity to an acceptable degree, researchers said.
"Machine learning" applied to data collected... (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - October 13, 2022 Category: Rheumatology Source Type: news
Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission ratea (based on the modified Mayo score [mMayo])b at week 38 of 47.9 percent, a higher rate than induction and maintenance treatment with either guselkumab alone (31.0 percent) or golimumab al...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
Drug Shows Promise Against Autoimmune Disease Scleroderma
MONDAY, Oct. 10, 2022 -- Researchers report early success with using an existing rheumatoid arthritis (RA) drug to treat systemic sclerosis, a rare but potentially devastating autoimmune condition.
The disease, a subset of scleroderma, hardens the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 10, 2022 Category: General Medicine Source Type: news
Tofacitinib Shows Promise Against Autoimmune Disease Scleroderma
MONDAY, Oct. 10, 2022 -- Researchers report early success with using an existing rheumatoid arthritis (RA) drug to treat systemic sclerosis, a rare but potentially devastating autoimmune condition.
The disease, a subset of scleroderma, hardens the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 10, 2022 Category: General Medicine Source Type: news
No Special Heart Risk With JAK Inhibitors, Study Finds
(MedPage Today) -- Patients taking Janus kinase (JAK) inhibitors for rheumatoid arthritis experienced similar cardiovascular outcomes as those using the tumor necrosis factor (TNF) blocker adalimumab (Humira), analysis of French national registry... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 7, 2022 Category: Cardiology Source Type: news
Pirfenidone Promising for RA-Linked Interstitial Lung Disease
TUESDAY, Oct. 4, 2022 -- Pirfenidone may slow the rate of decline of forced vital capacity (FVC) among patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD), according to a study published online Sept. 5 in The Lancet... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 4, 2022 Category: Pharmaceuticals Source Type: news
Clinical Predictors of Methotrexate Response in RA Patients Clinical Predictors of Methotrexate Response in RA Patients
Could certain factors determine treatment response to methotrexate in rheumatoid arthritis patients? A new study uses a machine learning approach to identify potential predictors.Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 4, 2022 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
Severe COVID-19 –Related Outcomes Found Worse in Men With RA Severe COVID-19 –Related Outcomes Found Worse in Men With RA
A retrospective electronic health record study of patients with rheumatoid arthritis and COVID-19 showed that men had more baseline comorbidities and increased risk of COVID-19 outcomes than females.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - September 29, 2022 Category: Infectious Diseases Tags: Rheumatology News Source Type: news
Group Therapy for Insomnia Studied in RA Patients
TUESDAY, Sept. 20, 2022 -- For patients with rheumatoid arthritis (RA) and insomnia, nurse-led group-based cognitive behavioral therapy for insomnia (CBT-I) does not have an impact on sleep efficiency measured immediately after the intervention, but... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 20, 2022 Category: Pharmaceuticals Source Type: news
Lupus, Psoriasis Patients May Face Greater Dangers After Heart Attack
THURSDAY, Sept. 15, 2022 -- People with autoimmune disorders like lupus, rheumatoid arthritis or psoriasis who suffer a heart attack are more likely to die or develop severe heart-related complications in the aftermath, a new study shows.
A heart... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 15, 2022 Category: General Medicine Source Type: news
Predicting Fractures in RA: Is FRAX Useful in the Modern Treatment Era?
(MedPage Today) -- AUSTIN, Texas – The Fracture Risk Assessment Tool (FRAX) for predicting risk of osteoporotic fractures appeared valid for rheumatoid arthritis (RA) patients treated in the era of biologics.
In a Canadian database study... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - September 11, 2022 Category: Endocrinology Source Type: news
Lupin, DKSH enter pact to commercials Alvotech biosimilars in Philippines
The biosimilars planned under this agreement include biosimilar Prolia (denosumab 60mg/ml) and Xgeva (denosumab 70 mg/ml) for treating osteoporosis, Simponi (golimumab) for treating rheumatoid arthritis, and Eylea (aflibercept) against wet-age macular degeneration as well as two undisclosed proposed biosimilars for immunology and oncology. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 7, 2022 Category: Pharmaceuticals Source Type: news
Pirfenidone Shows Hints of Benefit for RA-Related Lung Disease
(MedPage Today) -- BARCELONA -- Rheumatoid arthritis patients with existing interstitial lung disease (ILD) had less decline in lung function when receiving the antifibrotic agent pirfenidone (Esbriet) relative to placebo in a randomized trial... (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - September 6, 2022 Category: Rheumatology Source Type: news
One Young Mom's Journey With Rheumatoid Arthritis
TUESDAY, Sept. 6, 2022 -- Nearly 10 years ago, Tania Morales was a busy working mom when she was suddenly struck by pain, joint stiffness and exhaustion.“I felt alarmed, where it got to a point where I was telling my husband,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 6, 2022 Category: General Medicine Source Type: news
